Restrictive Cardiomyopathy (RCM) - Epidemiology Forecast - 2034

Restrictive Cardiomyopathy (RCM) - Epidemiology Forecast - 2034

Key Highlights

DelveInsight’s analyst projects that the total number of Restrictive Cardiomyopathy cases in 7MM were approximately 73 thousand in 2023 and these cases are further expected to increase during the forecasted period (2024–2034).

According to DelveInsight’s analysis, the total number of Diagnosed Prevalent Cases in the US was found to be 36 thousand in 2023 and is estimated to increase with a significant CAGR throughout the forecast period.

In 2023, the total number of diagnosed prevalent cases of RCM was 35 thousand in EU4 and the UK, which is anticipated to increase during the study period [2020–2034].

According to DelveInsight’s estimates, Japan accounted for 2% of the total Diagnosed Prevalent Cases of RCM in the 7MM in 2023.

DelveInsight’s “Restrictive Cardiomyopathy (RCM)– Epidemiology – 2034” report delivers an in-depth understanding of Restrictive Cardiomyopathy, historical and forecasted epidemiology of Restrictive Cardiomyopathy in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Restrictive Cardiomyopathy Disease Understanding

Restrictive Cardiomyopathy Overview

Restrictive cardiomyopathy (RCM) is a heart condition characterized by stiffness of the heart muscle, impairing its ability to fill properly with blood during the relaxation phase of the cardiac cycle. This stiffness restricts the heart’s capacity to pump effectively, leading to symptoms of heart failure.

RCM can be caused by various factors, including infiltrative diseases such as amyloidosis, hemochromatosis, or sarcoidosis, where abnormal substances accumulate in the heart muscle. Other causes may include storage diseases, endomyocardial fibrosis, radiation therapy, genetic factors, and systemic diseases like connective tissue disorders.

Symptoms of RCM typically manifest as heart failure symptoms, including shortness of breath, especially with exertion or when lying flat (orthopnea), fatigue, weakness, swelling in the legs and abdomen (edema), abdominal discomfort due to liver congestion, palpitations, irregular heartbeats, and exercise intolerance. These symptoms may worsen over time as the heart’s ability to pump effectively becomes increasingly compromised.

Restrictive Cardiomyopathy Diagnosis

Diagnosing RCM typically involves a combination of medical history assessment, physical examination, and various diagnostic tests. Medical professionals may look for signs and symptoms such as shortness of breath, fatigue, and fluid retention. Diagnostic tests commonly used to confirm RCM include echocardiography, which can show the characteristic features of stiffened heart chambers, and cardiac MRI, which provides detailed images of the heart’s structure and function. Additional tests like cardiac catheterization or endomyocardial biopsy may be performed to evaluate the heart’s function further and to determine the underlying cause of the RCM.

Further details related to diagnosis are provided in the report…

Restrictive Cardiomyopathy Epidemiology

As the market is derived using the patient-based model, the Restrictive Cardiomyopathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of RCM and Gender-specific Diagnosed Prevalent Cases of RCM in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

According to DelveInsight estimations, 73 thousand Diagnosed Prevalent Cases of Restrictive Cardiomyopathy were found in 2023 in the 7MM.

As per DelveInsight’s estimations, the total number of diagnosed prevalent cases with Restrictive Cardiomyopathy in the United States were 36 thousand in 2023 and are projected to increase during the forecast period.

According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of Restrictive Cardiomyopathy in EU4 and the UK were found to be 35 thousand in 2023. The highest proportion of Restrictive Cardiomyopathy cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.

The estimates show the number of Restrictive Cardiomyopathy cases in Japan was found to be 1 thousand in 2023, which is estimated to decrease by 2034.

The gender-specific diagnosed prevalent cases of RCM in the 7MM were 32 thousand for females and 41 thousand for males in 2023 and are expected to increase within the forecast period (2024–2034).

Restrictive Cardiomyopathy Cases in EU4 and the UK

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the State University of New York at Stony Brook Health Sciences Center, US, Mayo Clinic, Rochester, Minnesota, US, National Naval Medical Center, San Diego, US, University and University Hospital Würzburg, Germany, La Timone Hospital, Marseille, France, University of Ferrara, Ferrara, Italy, Hospital Central de Asturias, University of Oviedo, Spain, Guy’s and St. Thomas’ Foundation Trust, London, United Kingdom, Nippon Medical School, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Restrictive Cardiomyopathy, explaining its causes, signs and symptoms, and currently available therapies.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Restrictive Cardiomyopathy Report Insights

Patient Population

Country-wise Epidemiology Distribution

Diagnosed Prevalent Cases of RCM

Gender-specific Diagnosed Prevalent Cases of RCM

Restrictive Cardiomyopathy Report Key Strengths

11 years Forecast

The 7MM Coverage

Restrictive Cardiomyopathy Epidemiology Segmentation

Restrictive Cardiomyopathy Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Restrictive Cardiomyopathy? What will be the growth opportunities across the 7MM concerning the patient population of Restrictive Cardiomyopathy?

What is the historical and forecasted Restrictive Cardiomyopathy patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the prevalent cases of RCM in Japan lower than the US?

Which country has a high patient share for RCM?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Restrictive Cardiomyopathy prevalence cases in varying geographies over the coming years.

A detailed overview of Gender-specific diagnosed prevalence of RCM.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Restrictive Cardiomyopathy Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Restrictive Cardiomyopathy (RCM) cases in 2023?

The highest cases of Restrictive Cardiomyopathy was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Restrictive Cardiomyopathy (RCM) cases in 2023?

The highest cases of Restrictive Cardiomyopathy were found in the US among the 7MM in 2023.